ClinicalTrials.gg
CompletedNCT01859702Updated Aug 7, 2013Results posted

Pharmacokinetic Evaluation of Moxifloxacin in Vigadexa® in Aqueous Humor Samples Following Preoperative Antibiotic/Steroid Dosing in Cataract Surgery Patients

A Phase 4 interventional study of Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution in Cataract, sponsored by Alcon Research. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-08-07.

Sponsored by Alcon Research (part of Alcon) · Phase 4, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing moxifloxacin in Cataract — 1 open to participants now, 1 under way, 1 of them phase 3. Moxifloxacin · Cataract.

Enrollment
10th of 12
36 · median 62
Started
2012
the only one that year
Phase 4
9 of 12
none open now
Registered
8th of 12
by date
Lead sponsor
4 of 12
Alcon Research

Among the 12 studies testing moxifloxacin in Cataract, this one is the 10th largest by enrollment, is the only one that started in 2012, is one of 9 in phase 4, and was the 8th registered.

Cataract

1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.

Browse Cataract studies →

Open to participants now

1 of the 12 studies testing moxifloxacin in Cataract is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About moxifloxacin

Moxifloxacin: first FDA approval 1999 (AVELOX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing moxifloxacin in Cataract, or all of them as a file.
02

Study summary

The purpose of this study was to determine the moxifloxacin aqueous penetration when dosing with a combination drug Vigadexa preoperatively in cataract patients.

03

Conditions studied

  • Cataract

Browse trials for

Keywords

  • Aqueous Humor
  • Moxifloxacin
  • Vigadexa
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Requires cataract surgery;
  • Acceptable health status (medical history, physical, laboratory and ophthalmologic exams);
  • Able to follow instructions and willing to attend all study visits;
  • Other protocol-defined inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Any known or suspected allergies/ to any of the test product components;
  • History of invasive intraocular surgery in the eye to be operated, within 4 months before enrollment;
  • Use of medications, as specified in protocol;
  • Severe dry eye syndrome;
  • Use of contact lenses two days before surgery until the last visit;
  • External eye disease, infection or inflammation of the eyes or eyelids;
  • Excessive bleeding tendency;
  • No vision in the eye not included in the study;
  • Pregnant or breastfeeding;
  • Other protocol-defined exclusion criteria may apply.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    VIGADEXA

    Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution, 1 drop instilled in the study eye 2 days before surgery, followed by 1 drop instilled 4 times a day the day before surgery. On the day of surgery, 1 drop was instilled 60 minutes prior to the procedure.

    Drug: Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution

Interventions

  • DrugMoxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution

    Drug page: Moxifloxacin

    Also known as: Vigadexa®

06

What researchers measure

Primary outcomes

  1. Mean Aqueous Humor Concentration of Moxifloxacin

    A 0.150 milliliter sample of the aqueous humor was obtained during cataract surgery. The concentration of moxifloxacin was measured by a validated procedure using high performance liquid-spectrometry.

    Time frame: Day 3 (operative day)

07

Results

Posted Aug 7, 2013

Participant flow

Subjects were recruited from one study center in Brazil.

Participant flow — Overall Study
MilestoneVIGADEXA
Started36
Completed31
Not completed5
Withdrew: Protocol deviation3
Withdrew: Adverse event2

Outcome measures

PrimaryMean Aqueous Humor Concentration of Moxifloxacin

A 0.150 milliliter sample of the aqueous humor was obtained during cataract surgery. The concentration of moxifloxacin was measured by a validated procedure using high performance liquid-spectrometry.

Time frame:
Day 3 (operative day)
Reported as:
Mean · nanograms per milliliter
Mean Aqueous Humor Concentration of Moxifloxacin
nanograms per milliliterVIGADEXA
Mean Aqueous Humor Concentration of Moxifloxacin1110.6 (857.5 to 1363.7)

Adverse events

Collected over Adverse events were collected for the duration of the study. An adverse event was defined as any untoward medical occurrence, or deterioration of a pre-existing medical condition, that occurred during or after test product administration.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VIGADEXA—0/36 (0%)2/36 (5.6%)
Most frequent other events
Most frequent other events
EventVIGADEXA
Hypertensive CrisisCardiac disorders2/36

Baseline characteristics

This reporting group includes all enrolled subjects who received all doses of the test product.

Age Continuous
Age Continuous(years)VIGADEXA
Mean71.2 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)VIGADEXA
Female21
Male14
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2013
First posted
May 22, 2013
Start
Apr 2012
Primary completionActual
Aug 2012
CompletionActual
Aug 2012
Results first posted
Aug 7, 2013
Last update
Aug 7, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01859702
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
May 22, 2013
Start date
Apr 2012
Primary completion
Aug 2012
Completion
Aug 2012
Results posted
Aug 7, 2013
Last update
Aug 7, 2013

Study contacts

Abayomi Ogundele, PharmD
study director · Alcon Research
Mauro Silveira de Queiroz Campos, MD
principal investigator · Federal University of São Paulo, Ophthalmology Service

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Moxifloxacin

Start the discussion